- Home
- AKBA vs KOS Comparison
AKBA vs KOS Comparison
Compare AKBA & KOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- KOS
- Stock Information
- Founded
- AKBA 2007
- KOS 2003
- Country
- AKBA United States
- KOS United States
- Employees
- AKBA N/A
- KOS N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- KOS Oil & Gas Production
- Sector
- AKBA Health Care
- KOS Energy
- Exchange
- AKBA Nasdaq
- KOS Nasdaq
- Market Cap
- AKBA 861.7M
- KOS 822.2M
- IPO Year
- AKBA 2014
- KOS 2011
- Fundamental
- Price
- AKBA $3.04
- KOS $1.66
- Analyst Decision
- AKBA Strong Buy
- KOS Buy
- Analyst Count
- AKBA 5
- KOS 6
- Target Price
- AKBA $6.90
- KOS $4.52
- AVG Volume (30 Days)
- AKBA 4.0M
- KOS 9.4M
- Earning Date
- AKBA 08-07-2025
- KOS 08-04-2025
- Dividend Yield
- AKBA N/A
- KOS N/A
- EPS Growth
- AKBA N/A
- KOS N/A
- EPS
- AKBA N/A
- KOS N/A
- Revenue
- AKBA $203,733,000.00
- KOS $1,488,836,000.00
- Revenue This Year
- AKBA $27.95
- KOS N/A
- Revenue Next Year
- AKBA $43.88
- KOS $11.18
- P/E Ratio
- AKBA N/A
- KOS N/A
- Revenue Growth
- AKBA 16.75
- KOS N/A
- 52 Week Low
- AKBA $1.24
- KOS $1.39
- 52 Week High
- AKBA $4.08
- KOS $5.08
- Technical
- Relative Strength Index (RSI)
- AKBA 34.84
- KOS 35.97
- Support Level
- AKBA $2.92
- KOS $1.69
- Resistance Level
- AKBA $3.44
- KOS $1.77
- Average True Range (ATR)
- AKBA 0.15
- KOS 0.13
- MACD
- AKBA -0.06
- KOS -0.03
- Stochastic Oscillator
- AKBA 13.79
- KOS 2.46
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About KOS Kosmos Energy Ltd. (DE)
Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.